|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||1.5700 - 1.5700|
|52 Week Range||0.7850 - 1.8190|
|Beta (5Y Monthly)||1.40|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.67|
Pharming Group N.V. ("Pharming" or the "Company") (Euronext Amsterdam: PHARM) announces today the launch of an offering (the "Offering") of approximately €125 million of senior unsecured convertible bonds due 2025 (the "Bonds"). The net proceeds of the issue of the Bonds will be used to redeem the approximately US$ 56 million loan with Orbimed Advisors in full, thereby reducing the Company's financing costs and extending its debt maturity through the period to approval of most of the Company's existing pipeline. The balance of the net proceeds will be used to support capital expenditure in relation to the expansion of the commercialisation and manufacturing infrastructure of the Company, and serve as funding for the launch of Pharming's recently acquired Leniolisib product and for additional acquisitions/inlicensing opportunities.
LEIDEN, Netherlands, July 26, 2019 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM) presents its (unaudited) interim financial report for the first half year ended 30 June 2019. The Company will hold a conference call at 13:00 CET / 07:00 EST today: dial-in details can be found on pages 4 and 5.